CEL-SCI CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
CEL-SCI CORPORATION (CVM) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 181.40 thousand shares for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2025-12-29
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 181.40K shares, a 176.39% increase from fiscal 2024.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 65.63K shares, a 96.82% decline from fiscal 2023.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 2.07M shares, a 1.21% increase from fiscal 2022.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 2.04M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month as first filed |
|---|---|---|
| 2025-09-30 | 181.40K shares 10-K · filed 2025-12-29 | |
| 2024-09-30 | 65.63K shares 10-K · filed 2025-12-29 | 1.97M shares 10-K · filed 2025-01-13 |
| 2023-09-30 | 2.07M shares 10-K · filed 2025-01-13 | |
| 2022-09-30 | 2.04M shares 10-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |